In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Selecta Biosciences (SELB), with a price target of $6.00. The company’s shares closed last Thursday at $1.93.
According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 19.6% and a 51.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and Biospecifics Technologies.
Currently, the analyst consensus on Selecta Biosciences is a Moderate Buy with an average price target of $5.40, which is a 217.6% upside from current levels. In a report issued on October 1, Needham also maintained a Buy rating on the stock with a $3.50 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.83 and a one-year low of $1.28. Currently, Selecta Biosciences has an average volume of 1.62M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.
